nosocomial pneumonia

Nosocomial pneumonia is one of the most common healthcare-associated infections and the most frequent in intensive care unit (ICU) patients. The clinical and economic consequences of nosocomial pneumonia are very significant, especially for …

The increasing number of infections caused by multidrug-resistant gram-negative bacteria in children is a serious problem all over the world. Ceftazidim-avibactam is a promising antimicrobial drug recently approved in Russia for use in pediatric …

In order to study etiology and antimicrobial resistance rates in Gram-negative pathogens of nosocomial pneumonia, a total of 1410 isolates obtained from sputum in 75 ICU patients with nosocomial pneumonia in 2012 and 2017 was tested. The most common …

Telavancin is a first marketed representative of semisinthetic lipoglycopeptides — new generation of glycopeptide antimicrobials. Telavancin is registered for the treatment of nosocomial pneumonia and skin and soft tissue infections caused by Gram(+) …

Nosocomial pneumonia (NP) is a serious challenge for modern medicine. NP leads to prolongation of the hospitalization and high mortality. Optimal approaches to the diagnosis and prophylaxis of NP remain subjects for further developmnet. Adequate and …